Cargando…

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer

Endocrine therapies are the main treatment strategies for the clinical management of hormone-dependent breast cancer. Despite prolonged time to recurrence in the adjuvant setting and the initial clinical responses in the metastatic setting, many patients eventually encounter tumour relapse due to ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Alataki, Anastasia, Dowsett, Mitch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254309/
https://www.ncbi.nlm.nih.gov/pubmed/35613334
http://dx.doi.org/10.1530/ERC-21-0293
_version_ 1784740668785033216
author Alataki, Anastasia
Dowsett, Mitch
author_facet Alataki, Anastasia
Dowsett, Mitch
author_sort Alataki, Anastasia
collection PubMed
description Endocrine therapies are the main treatment strategies for the clinical management of hormone-dependent breast cancer. Despite prolonged time to recurrence in the adjuvant setting and the initial clinical responses in the metastatic setting, many patients eventually encounter tumour relapse due to acquired resistance to these agents. Other patients experience a lack of tumour regression at the beginning of treatment indicating de novo resistance that significantly limits its efficacy in the clinic. There is compelling evidence that human epidermal growth factor receptor-2 (HER2) overexpression contributes to resistance to endocrine therapies in oestrogen receptor-positive (ER+) breast cancer. ER+/HER2+ tumours comprise about 10% of all breast cancer cases and about 60% of the whole set of HER2+ tumours. Most patients with primary ER+/HER2+ disease will receive antibody-based HER2-targeted therapy, but this is generally for no more than one year while endocrine treatment is usually for at least 5 years. A number of HER2-kinase inhibitors are also now in clinical use or in clinical trials, and the interaction of these with endocrine treatment may differ from that of antibody treatment. In this review article, we aim to summarise knowledge on molecular mechanisms of breast cancer resistance to endocrine therapies attributable to the impact of HER2 signalling on endocrine sensitivity, to discuss data from clinical trials addressing the role of HER2 in the development of endocrine resistance in the metastatic, neoadjuvant and adjuvant settings and to explore rational new therapeutic strategies.
format Online
Article
Text
id pubmed-9254309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-92543092022-07-05 Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer Alataki, Anastasia Dowsett, Mitch Endocr Relat Cancer Review Endocrine therapies are the main treatment strategies for the clinical management of hormone-dependent breast cancer. Despite prolonged time to recurrence in the adjuvant setting and the initial clinical responses in the metastatic setting, many patients eventually encounter tumour relapse due to acquired resistance to these agents. Other patients experience a lack of tumour regression at the beginning of treatment indicating de novo resistance that significantly limits its efficacy in the clinic. There is compelling evidence that human epidermal growth factor receptor-2 (HER2) overexpression contributes to resistance to endocrine therapies in oestrogen receptor-positive (ER+) breast cancer. ER+/HER2+ tumours comprise about 10% of all breast cancer cases and about 60% of the whole set of HER2+ tumours. Most patients with primary ER+/HER2+ disease will receive antibody-based HER2-targeted therapy, but this is generally for no more than one year while endocrine treatment is usually for at least 5 years. A number of HER2-kinase inhibitors are also now in clinical use or in clinical trials, and the interaction of these with endocrine treatment may differ from that of antibody treatment. In this review article, we aim to summarise knowledge on molecular mechanisms of breast cancer resistance to endocrine therapies attributable to the impact of HER2 signalling on endocrine sensitivity, to discuss data from clinical trials addressing the role of HER2 in the development of endocrine resistance in the metastatic, neoadjuvant and adjuvant settings and to explore rational new therapeutic strategies. Bioscientifica Ltd 2022-05-25 /pmc/articles/PMC9254309/ /pubmed/35613334 http://dx.doi.org/10.1530/ERC-21-0293 Text en © The authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Alataki, Anastasia
Dowsett, Mitch
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
title Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
title_full Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
title_fullStr Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
title_full_unstemmed Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
title_short Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
title_sort human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254309/
https://www.ncbi.nlm.nih.gov/pubmed/35613334
http://dx.doi.org/10.1530/ERC-21-0293
work_keys_str_mv AT alatakianastasia humanepidermalgrowthfactorreceptor2andendocrineresistanceinhormonedependentbreastcancer
AT dowsettmitch humanepidermalgrowthfactorreceptor2andendocrineresistanceinhormonedependentbreastcancer